晚期非小细胞肺癌中β-tubulin Ⅲ表达水平对化学治疗敏感性的影响
| 作者: |
1陈佳,
1何松,
1王淼舟,
1郭燕,
1张晓东,
1吉志固,
1朱亚芳,
1陆俊国,
1陶玉,
1朱兴华,
1王建红,
1杨书云,
1尹海兵,
1谭清和
1 江苏省南通市肿瘤医院肿瘤内科, 江苏 南通 226361 |
| 通讯: |
谭清和
Email: tanqinghe@csco.org.cn |
| DOI: | 10.3978/j.issn.2095-6959.2013.01.006 |
| 基金: | 江苏省卫生厅面上项目(H200867) |
摘要
目的: 分析非小细胞肺癌(non-small cell lung cancer,NSCLC)患者β-tubulin Ⅲ的表达水平与化学治疗(化疗)敏感性的关系。方法: 经病理确诊的晚期NSCLC患者以1:2随机分配至对照组和基因型组:对照组使用吉西他滨联合顺铂化疗;基因型组根据ERCC1及RRM1的表达情况进行个体化治疗。检测病理标本中β-tubulin Ⅲ 的表达水平,比较β-tubulin Ⅲ蛋白表达水平与临床疗效之间的关系。结果: 基因型组最终有118例NSCLC病例可评价,均可成功检测β-tubulin Ⅲ的表达情况。对照组有效率(37.5%)与基因型组有效率(47.5%)比较,差异无统计学意义(P>0.05)。基因型组中各组间有效率比较,差异无统计学意义(P>0.05);但β-tubulin Ⅲ低表达组有效率(55.1%)显著高于β-tubulin Ⅲ高表达组(36.7%,P<0.05)。结论: 在晚期NSCLC腺癌亚型中,β-tubulin Ⅲ低表达患者疗效较好,β-tubulin Ⅲ高表达可能意味着对多西他赛耐药。
关键词：
Effect of beta-tubulin Ⅲ expression levels on chemotherapy sensitivity for advanced non-small cell lung cancer
CorrespondingAuthor: TAN Qinghe Email: tanqinghe@csco.org.cn
DOI: 10.3978/j.issn.2095-6959.2013.01.006
Abstract
Objective: To analyze the relation between β-tubulin Ⅲ expression level and chemosensitivity in non-small cell lung cancer (NSCLC). Methods: The patients were divided into a control group and a genotype group with a proportion of 1:2. The control group received the treatment of gemcitabin and cisplatin, while the genotype group received individual therapy according to the level of ERCC1 and RRM1. The correlation between β-tubulin Ⅲ expression level and chemosensitivity in NSCLC was analyzed. Results: β-Tubulin Ⅲ expression was detected in all patients in the genotype group. Compared with the genotype group (47.5%), efficiency in the control group (37.5%) was not significantly different. Efficiency in patients with low expression of β-tubulin Ⅲ was significantly higher than that of patients with high expression of β-tubulin Ⅲ (55.1% vs 36.7%, P<0.05). Conclusion: In advanced NSCLC subtypes, patients with low expression of β-tubulin Ⅲ have good therapeutic effect. High β-tubulin Ⅲ expression may indicate resistance to docetaxel.